8.74
-0.07 (-0.79%)
| Penutupan Terdahulu | 8.81 |
| Buka | 9.00 |
| Jumlah Dagangan | 1,417,294 |
| Purata Dagangan (3B) | 2,166,214 |
| Modal Pasaran | 1,392,049,152 |
| Harga / Pendapatan (P/E TTM) | 124.86 |
| Harga / Pendapatan (P/E Ke hadapan) | 17.18 |
| Harga / Jualan (P/S) | 3.41 |
| Harga / Buku (P/B) | 1.31 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Nov 2025 |
| Margin Keuntungan | -0.67% |
| Margin Operasi (TTM) | 7.19% |
| EPS Cair (TTM) | -0.020 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 9.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 28.51% |
| Nisbah Semasa (MRQ) | 2.78 |
| Aliran Tunai Operasi (OCF TTM) | 93.52 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 71.36 M |
| Pulangan Atas Aset (ROA TTM) | 1.12% |
| Pulangan Atas Ekuiti (ROE TTM) | -0.25% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Health Information Services (US) | Menurun | Menurun |
| Health Information Services (Global) | Menurun | Menurun | |
| Stok | Certara, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | -1.5 |
| Osilator Teknikal | 0.5 |
| Purata | 0.63 |
|
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region. |
|
| Sektor | Healthcare |
| Industri | Health Information Services |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 2.48% |
| % Dimiliki oleh Institusi | 100.90% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 13.00 (Leerink Partners, 48.74%) | Beli |
| 13.00 (Barclays, 48.74%) | Beli | |
| Median | 12.00 (37.30%) | |
| Rendah | 9.00 (BMO Capital, 2.98%) | Pegang |
| Purata | 11.83 (35.36%) | |
| Jumlah | 4 Beli, 2 Pegang | |
| Harga Purata @ Panggilan | 8.98 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Keybanc | 08 Jan 2026 | 12.00 (37.30%) | Beli | 9.67 |
| Leerink Partners | 06 Jan 2026 | 13.00 (48.74%) | Beli | 9.57 |
| Morgan Stanley | 18 Dec 2025 | 12.00 (37.30%) | Pegang | 8.88 |
| Barclays | 15 Dec 2025 | 13.00 (48.74%) | Beli | 8.74 |
| 07 Nov 2025 | 14.00 (60.18%) | Beli | 8.67 | |
| Stephens & Co. | 12 Dec 2025 | 12.00 (37.30%) | Beli | 8.58 |
| BMO Capital | 13 Nov 2025 | 9.00 (2.97%) | Pegang | 8.41 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 29 Jan 2026 | Pengumuman | Certara to Report Fourth Quarter and Full Year 2025 Financial Results on February 26th, 2025 |
| 12 Dec 2025 | Pengumuman | AI Creation Engines Transform Biotech as Wellness Tech Captures Growth Wave |
| 11 Dec 2025 | Pengumuman | Certara Appoints Jon Resnick as Chief Executive Officer |
| 06 Nov 2025 | Pengumuman | Certara Reports Third Quarter 2025 Financial Results |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |